Mette Tuxen Faber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mette Tuxen Faber has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Susanne Kriiger Kjaer
Unit of Virus, Lifestyle and Genes Danish Cancer Institute Copenhagen Denmark
3 shared publications - Bo Terning Hansen
Norwegian Institute of Public Health, Oslo, Norway
2 shared publications - Louise Baandrup
Unit of Virus, Lifestyle and Genes, Danish Cancer Institute, Strandboulevarden 49, 2100 Copenhagen O, Denmark; Department of Pathology, Zealand University Hospital, Sygehusvej 10, 4000 Roskilde, Denmark; Department of Clinical Medicine, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen N, Denmark
2 shared publications Louise T. Thomsen
Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Denmark
2 shared publicationsS.K. Kjaer
Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Strandboulevarden 49, DK-2100 Copenhagen, Denmark; Department of Gynecology, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark
2 shared publicationsSusanne K. Kjaer
Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Denmark
2 shared publications
Latest Publications
- 10 May 2023
- Published by SAGE Publications in Scandinavian Journal of Public Health
- Vol. 52 (5) , 616-623
Factors associated with teenage pregnancy in the Scandinavian countries
Aims: Teenage pregnancy may have negative consequences for the mother and the infant. The aim of the study was to examine whether selected individual factors occurring early in life were associated with teenage pregnancy. Methods: In a population-based, cross-sectional questionnaire study among 34,455 women from Denmark, Norway, and Sweden aged 20–45 years, who had first sexual intercourse (FSI) at age 13–19 years, we assessed the association between early smoking and drinking initiation (i.e., before the age of 13), contraceptive use at FSI, and teenage pregnancy. Log-linear binary regression models were fitted to estimate the relative risk (RR) with 95% confidence intervals (CIs) of teenage pregnancy according to the three exposure variables, overall and by age at FSI. Furthermore, the outcomes of the teenage pregnancies were examined according to age at FSI. Results: Teenage pregnancy occurred in 11% of the population. Both early smoking initiation (RR: 1.6; 95% CI: 1.4–1.8), early drinking initiation (RR: 1.2; 95% CI: 1.0–1.4), and non-use of contraceptives at FSI (RR: 1.9; 95% CI: 1.8–2.0) were associated with teenage pregnancy. The associations for early smoking initiation and non-use of contraceptives remained when analyses were stratified by age at FSI. Almost 60% of all teenage pregnant women had an induced abortion and less than 30% gave birth. Conclusions: Individual factors, including early smoking and drinking initiation, and non-use of contraceptives at FSI, were associated with teenage pregnancy regardless of age at FSI. This emphasizes the necessity of focusing on early risk-taking behavior as a potential modifier to prevent teenage pregnancy.
- 10 May 2023
- Published by SAGE Publications in Scandinavian Journal of Public Health
- Vol. 52 (5) , 616-623
Factors associated with teenage pregnancy in the Scandinavian countries
Aims: Teenage pregnancy may have negative consequences for the mother and the infant. The aim of the study was to examine whether selected individual factors occurring early in life were associated with teenage pregnancy. Methods: In a population-based, cross-sectional questionnaire study among 34,455 women from Denmark, Norway, and Sweden aged 20–45 years, who had first sexual intercourse (FSI) at age 13–19 years, we assessed the association between early smoking and drinking initiation (i.e., before the age of 13), contraceptive use at FSI, and teenage pregnancy. Log-linear binary regression models were fitted to estimate the relative risk (RR) with 95% confidence intervals (CIs) of teenage pregnancy according to the three exposure variables, overall and by age at FSI. Furthermore, the outcomes of the teenage pregnancies were examined according to age at FSI. Results: Teenage pregnancy occurred in 11% of the population. Both early smoking initiation (RR: 1.6; 95% CI: 1.4–1.8), early drinking initiation (RR: 1.2; 95% CI: 1.0–1.4), and non-use of contraceptives at FSI (RR: 1.9; 95% CI: 1.8–2.0) were associated with teenage pregnancy. The associations for early smoking initiation and non-use of contraceptives remained when analyses were stratified by age at FSI. Almost 60% of all teenage pregnant women had an induced abortion and less than 30% gave birth. Conclusions: Individual factors, including early smoking and drinking initiation, and non-use of contraceptives at FSI, were associated with teenage pregnancy regardless of age at FSI. This emphasizes the necessity of focusing on early risk-taking behavior as a potential modifier to prevent teenage pregnancy.
- Open Access
- 15 June 2022
- Published by Wiley in International Journal of Cancer
- Vol. 151 (8) , 1240-1247
A nationwide longitudinal study on risk factors for progression of anal intraepithelial neoplasia grade 3 to anal cancer
Little is known about risk factors for progression of high‐grade anal intraepithelial neoplasia (AIN) to anal squamous cell carcinoma (ASCC). In this large, population‐based study, we assess the role of factors related to immune status for the risk of ASCC among individuals from the general population with a diagnosis of AIN3. Individuals diagnosed with AIN3 during 1985‐2016 were identified in the Danish Pathology Registry and followed for subsequent development of ASCC. The study population was linked to the National Patient Registry, the Danish Prescription Registry and the Danish HIV Cohort Study for information on autoimmune disease, genital warts and HIV status. To study the progression rate, Cox regression models with hazard ratios (HR) and 95% confidence intervals (CI) were applied with time since AIN3 as the underlying time scale and with adjustment for age at AIN3 diagnosis, year of AIN3 diagnosis and sex. The study population comprised 1222 individuals with AIN3 contributing 12 824 person‐years of follow‐up. Ninety‐seven individuals (7.9%) developed ASCC. Individuals registered with an autoimmune disease or genital warts before and/or after the AIN3 diagnosis had an increased rate of progression to ASCC compared to individuals without these conditions. People living with HIV had a higher progression rate than HIV‐negative individuals (HR = 4.25; 95% CI: 1.87‐9.65) with the highest progression rate among those with CD4 count ≤200 cells/μL. These associations may be caused by an interplay between HPV infection and immunosuppression.
- 15 June 2022
- Published by Wiley in International Journal of Cancer
- Vol. 151 (8) , 1240-1247
Open AccessA nationwide longitudinal study on risk factors for progression of anal intraepithelial neoplasia grade 3 to anal cancer
Little is known about risk factors for progression of high‐grade anal intraepithelial neoplasia (AIN) to anal squamous cell carcinoma (ASCC). In this large, population‐based study, we assess the role of factors related to immune status for the risk of ASCC among individuals from the general population with a diagnosis of AIN3. Individuals diagnosed with AIN3 during 1985‐2016 were identified in the Danish Pathology Registry and followed for subsequent development of ASCC. The study population was linked to the National Patient Registry, the Danish Prescription Registry and the Danish HIV Cohort Study for information on autoimmune disease, genital warts and HIV status. To study the progression rate, Cox regression models with hazard ratios (HR) and 95% confidence intervals (CI) were applied with time since AIN3 as the underlying time scale and with adjustment for age at AIN3 diagnosis, year of AIN3 diagnosis and sex. The study population comprised 1222 individuals with AIN3 contributing 12 824 person‐years of follow‐up. Ninety‐seven individuals (7.9%) developed ASCC. Individuals registered with an autoimmune disease or genital warts before and/or after the AIN3 diagnosis had an increased rate of progression to ASCC compared to individuals without these conditions. People living with HIV had a higher progression rate than HIV‐negative individuals (HR = 4.25; 95% CI: 1.87‐9.65) with the highest progression rate among those with CD4 count ≤200 cells/μL. These associations may be caused by an interplay between HPV infection and immunosuppression.
- 1 January 2022
- Published by Elsevier in Gynecologic Oncology
- Vol. 164 (1) , 98-104
Trends in survival of epithelial ovarian/tubal cancer by histology and socioeconomic status in Denmark 1996–2017
- 1 January 2022
- Published by Elsevier in Gynecologic Oncology
- Vol. 164 (1) , 98-104
Trends in survival of epithelial ovarian/tubal cancer by histology and socioeconomic status in Denmark 1996–2017
- 1 May 2021
- Published by Elsevier in Gynecologic Oncology
- Vol. 161 (2) , 553-558
A Danish nationwide study of risk factors associated with Type I and Type II endometrial cancer
- 1 May 2021
- Published by Elsevier in Gynecologic Oncology
- Vol. 161 (2) , 553-558
A Danish nationwide study of risk factors associated with Type I and Type II endometrial cancer
- 21 October 2020
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 100 (3) , 436-443
Borderline ovarian tumors in Denmark 1997‐2018: Time trends in incidence by histology, age and educational level
Introduction: After some decades with an increasing incidence of borderline ovarian tumors, more recent studies have observed that the incidence rate seems to be leveling off or declining. In this study, we describe the incidence of borderline ovarian tumors in Denmark 1997‐2018 by histology, age at diagnosis and educational level.Material and methods: All borderline ovarian tumors registered in the Danish Pathology Registry during 1997‐2018 were identified and individual‐level educational information was retrieved from nationwide registers. Age‐standardized incidence rates were estimated according to histology, age at diagnosis and educational level. To investigate incidence trends over time, the average annual percentage change and corresponding 95% confidence intervals (CIs) were estimated using Poisson regression.Results: We identified 3927 women with borderline ovarian tumors during the study period, of which 1997 (50.9%) were serous and 1743 (44.4%) were mucinous. The age‐standardized incidence rate of serous borderline ovarian tumors did not change significantly over calendar time (average annual percentage change = −0.13, 95% confidence interval [CI] −1.13 to 0.88). For mucinous tumors, the age‐standardized incidence rate was also relatively stable during the first half of the study period, followed by a decrease from 2.56 to 1.25 per 100 000 person‐years between 2007‐2011 and 2017‐2018. Over the entire study period, the incidence rate of mucinous borderline tumors declined on average by 2.91% (95% CI −4.24 to −1.51) per year. The incidence of both types of borderline ovarian tumors seemed to be highest among women with a low educational level. Over calendar time, the incidence of mucinous tumors decreased in all educational groups, whereas the incidence of serous tumors decreased exclusively in women with a high educational level. Time trends did not differ markedly by age at diagnosis.Conclusions: In Denmark, the incidence of serous borderline ovarian tumors was stable during 1997‐2018, whereas the incidence of mucinous borderline ovarian tumors decreased. The incidence rates of both types of borderline ovarian tumors tended to be highest among women with a low educational level throughout the study period.
- 21 October 2020
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 100 (3) , 436-443
Borderline ovarian tumors in Denmark 1997‐2018: Time trends in incidence by histology, age and educational level
Introduction: After some decades with an increasing incidence of borderline ovarian tumors, more recent studies have observed that the incidence rate seems to be leveling off or declining. In this study, we describe the incidence of borderline ovarian tumors in Denmark 1997‐2018 by histology, age at diagnosis and educational level.Material and methods: All borderline ovarian tumors registered in the Danish Pathology Registry during 1997‐2018 were identified and individual‐level educational information was retrieved from nationwide registers. Age‐standardized incidence rates were estimated according to histology, age at diagnosis and educational level. To investigate incidence trends over time, the average annual percentage change and corresponding 95% confidence intervals (CIs) were estimated using Poisson regression.Results: We identified 3927 women with borderline ovarian tumors during the study period, of which 1997 (50.9%) were serous and 1743 (44.4%) were mucinous. The age‐standardized incidence rate of serous borderline ovarian tumors did not change significantly over calendar time (average annual percentage change = −0.13, 95% confidence interval [CI] −1.13 to 0.88). For mucinous tumors, the age‐standardized incidence rate was also relatively stable during the first half of the study period, followed by a decrease from 2.56 to 1.25 per 100 000 person‐years between 2007‐2011 and 2017‐2018. Over the entire study period, the incidence rate of mucinous borderline tumors declined on average by 2.91% (95% CI −4.24 to −1.51) per year. The incidence of both types of borderline ovarian tumors seemed to be highest among women with a low educational level. Over calendar time, the incidence of mucinous tumors decreased in all educational groups, whereas the incidence of serous tumors decreased exclusively in women with a high educational level. Time trends did not differ markedly by age at diagnosis.Conclusions: In Denmark, the incidence of serous borderline ovarian tumors was stable during 1997‐2018, whereas the incidence of mucinous borderline ovarian tumors decreased. The incidence rates of both types of borderline ovarian tumors tended to be highest among women with a low educational level throughout the study period.
- 1 February 2020
- Published by Elsevier in Preventive Medicine
- Vol. 131, 105944
Factors associated with condom use during sexual intercourse with a new partner among Scandinavian women
- 1 February 2020
- Published by Elsevier in Preventive Medicine
- Vol. 131, 105944
Factors associated with condom use during sexual intercourse with a new partner among Scandinavian women
- 19 November 2019
- Published by Wiley in Oral Diseases
- Vol. 26 (2) , 484-488
Prevalence, type distribution and risk factors for oral HPV in Danish renal transplant recipients
Objective: To assess the prevalence and type distribution of oral human papillomavirus (HPV) among renal transplant recipients (RTRs) and healthy controls and to examine risk factors for oral HPV among RTRs.Materials and Methods: During 2016‐2017 we recruited 250 RTRs and 250 controls. Oral samples were tested for HPV DNA with INNO‐LiPA HPV Genotyping Extra II. All participants answered a questionnaire on lifestyle and sexual behaviour, and characteristics of RTRs were obtained from medical files. We assessed prevalence and type distribution of oral HPV. Using logistic regression, the risk of oral HPV and risk factors for oral HPV among RTRs were estimated as odds ratios (OR) with 95% confidence intervals (CI).Results: Overall, 30 RTRs (12.1%) and 26 controls (10.4%) were oral HPV positive (OR = 1.14; 95% CI: 0.64–2.05). Female RTRs tended to have a higher oral HPV prevalence than controls (OR = 1.73; 95% CI: 0.63–4.77), while no difference was observed among men. HPV51 was the commonest genotype. Sexual behaviour tended to be associated with oral HPV among RTRs.Conclusions: There was no overall difference in oral HPV prevalence between RTRs and controls, but female RTRs tended to have a higher prevalence of oral HPV than controls.
- 19 November 2019
- Published by Wiley in Oral Diseases
- Vol. 26 (2) , 484-488
Prevalence, type distribution and risk factors for oral HPV in Danish renal transplant recipients
Objective: To assess the prevalence and type distribution of oral human papillomavirus (HPV) among renal transplant recipients (RTRs) and healthy controls and to examine risk factors for oral HPV among RTRs.Materials and Methods: During 2016‐2017 we recruited 250 RTRs and 250 controls. Oral samples were tested for HPV DNA with INNO‐LiPA HPV Genotyping Extra II. All participants answered a questionnaire on lifestyle and sexual behaviour, and characteristics of RTRs were obtained from medical files. We assessed prevalence and type distribution of oral HPV. Using logistic regression, the risk of oral HPV and risk factors for oral HPV among RTRs were estimated as odds ratios (OR) with 95% confidence intervals (CI).Results: Overall, 30 RTRs (12.1%) and 26 controls (10.4%) were oral HPV positive (OR = 1.14; 95% CI: 0.64–2.05). Female RTRs tended to have a higher oral HPV prevalence than controls (OR = 1.73; 95% CI: 0.63–4.77), while no difference was observed among men. HPV51 was the commonest genotype. Sexual behaviour tended to be associated with oral HPV among RTRs.Conclusions: There was no overall difference in oral HPV prevalence between RTRs and controls, but female RTRs tended to have a higher prevalence of oral HPV than controls.
- 21 June 2017
- Published by Wiley in International Journal of Cancer
- Vol. 141 (6) , 1161-1169
Prevalence and type distribution of human papillomavirus in squamous cell carcinoma and intraepithelial neoplasia of the vulva
In this updated systematic review and meta-analysis we estimate the pooled prevalence of human papillomavirus (HPV) DNA and HPV type distribution in squamous cell carcinoma of the vulva (vulvar cancer) and vulvar intraepithelial neoplasia (VIN). PubMed, Embase, and Cochrane Library databases were used to identify studies published between 1990 and 2015 and using a PCR-based or hybrid capture test to evaluate the presence of HPV DNA in vulvar cancer or VIN. Pooled estimates of the HPV prevalence with corresponding 95% confidence intervals (CI) were calculated based on a random effects model. The I2 statistic was used to describe the amount of heterogeneity. In meta-regression analyses potential sources of heterogeneity were evaluated. We identified 92 eligible papers, comprising altogether 5015 cases of vulvar cancer (64 papers) and 2764 cases of VIN (48 papers). The pooled prevalence of HPV in vulvar cancer was 39.7% (95% CI: 35.1–44.4%). Overall, 76.3% (95% CI: 70.1–82.1%) of VIN lesions tested HPV-positive, while the HPV prevalence in new subcategories of VIN, uVIN and dVIN, was 86.2% (95% CI: 73.5–95.5%) and 2.0% (95% CI: 0–10.0%), respectively. Substantial between-study heterogeneity was observed (vulvar cancer: I2 = 88.4%; VIN: I2 = 90.7%) with the largest variation between geographical regions. Among HPV-positive cases the predominant high-risk HPV type was HPV16, followed by HPV33 and HPV18. HPV6 was detected as a single infection in a small subset of VIN and vulvar cancer samples. Thus, HPV vaccination targeting these HPV types may prevent a substantial number of vulvar lesions.
- 21 June 2017
- Published by Wiley in International Journal of Cancer
- Vol. 141 (6) , 1161-1169
Prevalence and type distribution of human papillomavirus in squamous cell carcinoma and intraepithelial neoplasia of the vulva
In this updated systematic review and meta-analysis we estimate the pooled prevalence of human papillomavirus (HPV) DNA and HPV type distribution in squamous cell carcinoma of the vulva (vulvar cancer) and vulvar intraepithelial neoplasia (VIN). PubMed, Embase, and Cochrane Library databases were used to identify studies published between 1990 and 2015 and using a PCR-based or hybrid capture test to evaluate the presence of HPV DNA in vulvar cancer or VIN. Pooled estimates of the HPV prevalence with corresponding 95% confidence intervals (CI) were calculated based on a random effects model. The I2 statistic was used to describe the amount of heterogeneity. In meta-regression analyses potential sources of heterogeneity were evaluated. We identified 92 eligible papers, comprising altogether 5015 cases of vulvar cancer (64 papers) and 2764 cases of VIN (48 papers). The pooled prevalence of HPV in vulvar cancer was 39.7% (95% CI: 35.1–44.4%). Overall, 76.3% (95% CI: 70.1–82.1%) of VIN lesions tested HPV-positive, while the HPV prevalence in new subcategories of VIN, uVIN and dVIN, was 86.2% (95% CI: 73.5–95.5%) and 2.0% (95% CI: 0–10.0%), respectively. Substantial between-study heterogeneity was observed (vulvar cancer: I2 = 88.4%; VIN: I2 = 90.7%) with the largest variation between geographical regions. Among HPV-positive cases the predominant high-risk HPV type was HPV16, followed by HPV33 and HPV18. HPV6 was detected as a single infection in a small subset of VIN and vulvar cancer samples. Thus, HPV vaccination targeting these HPV types may prevent a substantial number of vulvar lesions.